Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.41 · Revenue $147.15M · 7 analysts
Est. EPS $0.45 · Revenue $157.29M · 7 analysts
Est. EPS $1.91 · Revenue $593.64M · 7 analysts
Est. EPS $0.45 · Revenue $153.64M · 2 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $517.1M | +16.0% | +8.1% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $66.4M | +174.9% | -11.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +69.6% | +4.1% | -0.1% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +14.3% | +296.0% | -10.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +12.8% | +136.9% | -17.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $126.6M | +98.5% | +33.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +24.5% | +71.1% | +23.2% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 3.0% | -29.8% | -1.3% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 8.15x | +72.1% | -1.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.4B | +8.2% | +3.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 0.82 vs 1.66 | -50.7% | 0.31 vs 0.41 | -24.2% |
| Revenue Surprise | $517.1M vs $511.7M | +1.1% | $150.3M vs $147.1M | +2.2% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Bhanji Muna | director | Common Stock | D | 1,864 | $42.97 |
| Jun 18, 2026 | EASTHAM KARIN | director | Common Stock | D | 3,200 | $52.78 |
| Jun 18, 2026 | EASTHAM KARIN | director | Common Stock | D | 529 | $53.55 |
| Jun 11, 2026 | EASTHAM KARIN | director | Common Stock | A | 5,272 | — |
| Jun 11, 2026 | JONES EVAN/ FA | director | Common Stock | A | 5,272 | — |
Operator: Good day and thank you for standing by. Welcome to Veracyte First Quarter 2026 Financial Results Webcast Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Kelly Gura, Director of Investor Relations. Kelly Gura: Good afternoon, everyone, and thank you for joining us today to review Veracyte's First quarter 2026 financial results. Joining me on the call are Marc Stapley, our Chief Executive Officer; and Rebecca Chambers, our Chief Financial Officer. Dr. John Leite, our Chief Commercial Officer, will also be available for Q&A. Earlier this afternoon, we issued a press release detailing our first quarter financial results, and we posted an accompanying presentation in the Investors section of our website. Before we begin, I'd like to remind you that statements we make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties, and the company can give no assurance they will prove to be correct. Additionally, we are not under any obligation to provide further updates on our business trends or our performance during the quarter. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte files with the Securities and Exchange Commission, including the most recent Forms 10-Q and 10-K. In addition, this call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures are included in today's earnings release accessible from the Investors section of Veracyte's website. I'm also pleased to highlight Veracyte's newly redesigned website, which makes it easier to access information on our test portfolio, including a publication search tool to help navigate our extensive and growing clinical evidence base. I will now turn the call over to Marc Stapley, Veracyte's CEO. Marc Stapley: Thank you, Kelly, and thank you all for joining us today. We had an excellent start to 2026. In the first quarter, we delivered strong double-digit revenue and volume growth, exceeded our profitability expectations and continued advancing key catalysts that position us well for long-term growth. This quarter highlights years of disciplined execution that have transformed Veracyte into a stronger, more focused, scalable company. Five years ago, we set out to make Decipher commercial success, grow our core franchises, expand operations, enhance clinical evidence and build a strong pipeline. We revitalized Afirma, made Decipher the top prostate cancer gene expression test, increased lab capacity threefold, improved turnaround time and the no result rate and surpassed a 25% adjusted EBITDA margin. Today, Veracyte is a diversified profitable company with a unique platform, multiple growth drivers, …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Marc A. Stapley | Chief Executive Officer & Director | USD 1,531,000 | Male | 1970 | Active |
Phillip G. Febbo | Chief Scientific & Medical Officer | USD 930,089 | — | 1966 | Active |
Rebecca Chambers | Executive Vice President & Chief Financial Officer | USD 911,950 | Female | 1978 | Active |
John Leite | Global Chief Commercial Officer | USD 846,485 | — | 1972 | Active |
Annie McGuire | Executive VP, General Counsel & Head of Market Access | USD 829,500 | Female | 1981 | Active |
Kevin Richard Haas | Chief Development and Technology Officer | — | — | 1985 | Active |
Steven French | Senior Vice President & Chief Information Officer | — | Male | — | Active |
Kelly Gura | Director of Investor Relations | — | Female | — | Active |
Keith Gligorich | Senior Vice President of Global Operations | — | — | — | Active |
Jonathan Wygant | Vice President & Chief Accounting Officer | — | Male | 1971 | Active |
Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bank of America Corp DE grew its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 14.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,448,897 shares of the biotechnology company's stock after buying an additional 185,929 shares during the period.
Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.
Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion.
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
